Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Wall Street Ends Mixed as Tech Stocks Struggle Ahead of Micron Earnings 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
South Korea Stocks Tumble as AI-Fueled Rally Faces Profit-Taking Pressure 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
New Zealand Fast-Tracks Gold Mining as Industry Revival Gains Momentum 
Singapore Inflation Stays Muted in May as Core CPI Misses Forecasts Ahead of MAS Review 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Sanofi will be acquiring mRNA developer, Translate Bio, and this was revealed on Monday, Aug. 4. The French pharmaceutical company headquartered in Paris was reported to have offered to buy the US-based company after experiencing setbacks in its attempt to produce its own brand of COVID-19 vaccine.
As per CNBC, Sanofi will purchase all the available shares of the Massachusetts-headquartered mRNA therapeutics company at $38.00 per share. The total equity value is around $3.2 billion, and it will be paid in cash.
An insider who cannot be identified because of the confidentiality of the deal shared that Translate Bio’s board will hold a meeting to discuss the offer. Another source revealed that Sanofi’s executive directors also convened last Sunday to talk about the potential acquisition.
At any rate, it was said that the boards of the two companies gave their approval for the deal. Translate Bio’s chief executive officer, and the firm’s largest shareholder are reportedly backing the takeover offer by Sanofi, and this was confirmed through a joint statement.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Sanofi’s CEO, Paul Hudson, said in a press release. “A fully owned platform allows us to develop additional opportunities in the fast-evolving mRNA space and we will also be able to accelerate our existing partnered programs already under development.”
Hudson added that with Translate Bio, aside from vaccines, Sanofi’s goal is to unravel the potential of messenger ribonucleic acid (mRNA) in other medical fields, including immunology, oncology, and rare diseases.
Prior to this recent acquisition, Sanofi and Translate Bio have actually been working together since 2018, and last year, they teamed up to develop an mRNA-based vaccine for COVID-19. In the third quarter of this year, they are expecting to get provisional results of their Phase I/II clinical trial.
Meanwhile, Reuters reported that shares of Sanofi went up by more than 70% to over $50 in extended trading. The financial terms of the French firm’s offer were not disclosed at this time, and Translate Bio's market value has also soared to around $2.2 billion at the close on Monday.
